Apolipoprotein L1 (APOL1) cation current in HEK-293 cells and in human podocytes-Reference-Cited by-同舟云学术

Apolipoprotein L1 (APOL1) cation current in HEK-293 cells and in human podocytes

Published:2022-11-30 Issue:3 Volume:475 Page:323-341
ISSN:0031-6768
Container-title:Pflügers Archiv - European Journal of Physiology
language:en
Short-container-title:Pflugers Arch - Eur J Physiol

Author:

Vandorpe David H.,Heneghan John F.,Waitzman Joshua S.,McCarthy Gizelle M.,Blasio Angelo,Magraner Jose M.,Donovan Olivia G.,Schaller Lena B.,Shah Shrijal S.,Subramanian Balajikarthick,Riella Cristian V.,Friedman David J.,Pollak Martin R.,Alper Seth L.

Publisher

Springer Science and Business Media LLC

Subject

Physiology (medical),Clinical Biochemistry,Physiology

Link

https://link.springer.com/content/pdf/10.1007/s00424-022-02767-8.pdf

Reference58 articles.

1. Aghajan M, Booten SL, Althage M, Hart CE, Ericsson A, Maxvall I, Ochaba J, Menschik-Lundin A, Hartleib J, Kuntz S, Gattis D, Ahlstrom C, Watt AT, Engelhardt JA, Monia BP, Magnone MC, Guo S (2019) Antisense oligonucleotide treatment ameliorates IFN-gamma-induced proteinuria in APOL1-transgenic mice. JCI Insight 4. https://doi.org/10.1172/jci.insight.126124

2. Akilesh S, Huber TB, Wu H, Wang G, Hartleben B, Kopp JB, Miner JH, Roopenian DC, Unanue ER, Shaw AS (2008) Podocytes use FcRn to clear IgG from the glomerular basement membrane. Proc Natl Acad Sci U S A 105:967–972. https://doi.org/10.1073/pnas.0711515105

3. Beckerman P, Bi-Karchin J, Park AS, Qiu C, Dummer PD, Soomro I, Boustany-Kari CM, Pullen SS, Miner JH, Hu CA, Rohacs T, Inoue K, Ishibe S, Saleem MA, Palmer MB, Cuervo AM, Kopp JB, Susztak K (2017) Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice. Nat Med 23:429–438. https://doi.org/10.1038/nm.4287

4. Bruggeman LA, Sedor JR, O’Toole JF (2021) Apolipoprotein L1 and mechanisms of kidney disease susceptibility. Curr Opin Nephrol Hypertens 30:317–323. https://doi.org/10.1097/MNH.0000000000000704

5. Bruggeman LA, Wu Z, Luo L, Madhavan SM, Konieczkowski M, Drawz PE, Thomas DB, Barisoni L, Sedor JR, O’Toole JF (2016) APOL1-G0 or APOL1-G2 transgenic models develop preeclampsia but not kidney disease. J Am Soc Nephrol 27:3600–3610. https://doi.org/10.1681/ASN.2015111220

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Two Levels of Podocyte Dysfunctions Induced by Apolipoprotein L1 Risk Variants;Kidney and Dialysis;2024-06-07

2. In Search of the Mechanism of APOL1 Kidney Disease;Journal of the American Society of Nephrology;2024-04-10

3. Interferon Upregulation Associates with Insulin Resistance in Humans;Current Diabetes Reviews;2024-03-18

4. APOL1 nephropathy – a population genetics success story;Current Opinion in Nephrology & Hypertension;2024-02-28

5. Apolipoprotein L1 (APOL1) renal risk variant-mediated podocyte cytotoxicity depends on African haplotype and surface expression;Scientific Reports;2024-02-14